Danielle Marie Brander, MD

Publications

Eichenberger, Emily M., Jennifer Saullo, Danielle Brander, Shih-Hsiu Wang, John R. Perfect, and Julia A. Messina. “A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy..” Med Mycol Case Rep 27 (March 2020): 17–21. https://doi.org/10.1016/j.mmcr.2019.12.007.

PMID
31879587
Full Text

Eyre, Toby A., Lindsey E. Roeker, Christopher P. Fox, Satyen H. Gohill, Renata Walewska, Harriet S. Walter, Francesco Forconi, et al. “The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia..” Br J Haematol, November 4, 2019. https://doi.org/10.1111/bjh.16271.

PMID
31682002
Full Text

Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al..” Br J Haematol 186, no. 4 (August 2019). https://doi.org/10.1111/bjh.15934.

PMID
31044417
Full Text

Davids, Matthew S., Danielle M. Brander, Haesook T. Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell, Jeffrey M. Hellman, et al. “Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial..” Lancet Haematol 6, no. 8 (August 2019): e419–28. https://doi.org/10.1016/S2352-3026(19)30104-8.

PMID
31208944
Full Text

Roeker, Lindsey E., Christopher P. Fox, Toby A. Eyre, Danielle M. Brander, John N. Allan, Stephen J. Schuster, Chadi Nabhan, et al. “Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice..” Clin Cancer Res 25, no. 14 (July 15, 2019): 4264–70. https://doi.org/10.1158/1078-0432.CCR-19-0361.

PMID
31004001
Full Text

Mato, Anthony R., Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, et al. “A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL..” Blood Adv 3, no. 10 (May 28, 2019): 1568–73. https://doi.org/10.1182/bloodadvances.2019000180.

PMID
31101647
Full Text

Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia..” Br J Haematol 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.

PMID
30443898
Full Text

Wierda, William G., John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019..” J Natl Compr Canc Netw 17, no. 1 (January 2019): 12–20. https://doi.org/10.6004/jnccn.2019.0002.

PMID
30659125
Full Text

Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL..” N Engl J Med 379, no. 26 (December 27, 2018): 2517–28. https://doi.org/10.1056/NEJMoa1812836.

PMID
30501481
Full Text

Mato, Anthony R., Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Bruce D. Cheson, et al. “Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial..” Am J Hematol 93, no. 11 (November 2018): 1394–1401. https://doi.org/10.1002/ajh.25261.

PMID
30132965
Full Text

Pages